

Antibodies to a phospholipase A₂ from *Vipera russelli* selectively neutralize venom neurotoxicity

S. KASTURI, L. M. S. RUDRAMMAJI & T. V. GOWDA *Department of Studies in Biochemistry, University of Mysore, Manasagangothri, Mysore, India*

Accepted for publication 12 February 1990

SUMMARY

Polyclonal antibodies to a purified neurotoxic phospholipase A₂ (PLA₂), VRV PL-VIII_a, from *Vipera russelli* venom were raised in rabbits. Anti-PL-VIII_a-Ig (γ -globulin fraction of rabbit antiserum injected with VRV PL-VIII_a) selectively neutralized the neurotoxicity of VRV PL-VIII_a, VRV PL-V, VRV PL-VI (neurotoxic PLA₂ of *V. russelli* venom) and whole *V. russelli* venom without affecting their PLA₂ activity, which clearly demonstrates that the catalytic site and the neurotoxic site (the site through which the PLA₂ binds to the nervous system) are distinct on a PLA₂ molecule. Anti-PL-VIII_a Ig did not have any effect on the oedema-inducing activity and indirect haemolytic activity of VRV PL-VIII_a, VRV PL-V and VRV PL-VI, which are attributed to the PLA₂ activity of the peptide, but inhibited their anti-coagulant potency.

INTRODUCTION

The venom phospholipase A₂ (PLA₂) (EC 3.1.1.4), along with their contribution in digesting the prey, induce pathological symptoms, including neurotoxic, myotoxic, cardiotoxic, haemolytic, anti-coagulant, convulsant and hypotensive effects. The presynaptic neurotoxins are highly potent toxins of snake venom and they are either basic PLA₂ *per se* or contain basic PLA₂ as an indispensable part of their structure (Kini & Iwanaga, 1986a). Attempts are being made to identify the relationship between the pharmacological properties and catalytic activity of PLA₂. Although the dissociation of enzymatic and pharmacological properties has been achieved to a certain extent, there is also considerable evidence in favour of the essential role of PLA₂ activity in toxicity (Kini & Iwanaga, 1986a, b).

Using hydropathy profiles, Kini & Iwanaga (1986a) predicted that the neurotoxic phospholipases have a distinct hydrophobic region around amino acid residues 80-110, which is the neurotoxic potential probably involved in the interaction with the synaptic membrane, which is absent in non-neurotoxic PLA₂.

Recently, a theoretical approach has been used to locate specific pharmacological sites in venom PLA₂ enzymes, and the prediction indicates the presence of specific sites associated with a particular pharmacological activity, and the absence of such

Abbreviations: Ag-Ab; antigen-antibody; i.p., intraperitoneal; ND, not determined; PC, phosphatidyl choline; PLA₂, phospholipase A₂; SDS, sodium dodecyl sulphate; VRV, *Vipera russelli* venom; w/w, weight/weight.

Correspondence: Dr T. V. Gowda, Dept. of Studies in Biochemistry, Manasagangothri, Mysore 570 006, India.

sites results in non-exhibition of those pharmacological effects (Kini & Evans, 1989). Their predictions are strengthened by previous results of the present authors. A neurotoxic PLA₂ of *Vipera russelli* venom, upon self-aggregation, loses its lethality and neurotoxicity, whereas there is a remarkable increase in its catalytic activity. Antibodies prepared against the same aggregated PLA₂ nullifies the lethality and neurotoxic symptoms, whereas its catalytic activity remains unaffected. Based on these results, the possible presence of distinct neurotoxic and catalytic sites on a PLA₂ molecule is suggested (Jayanthi, Kasturi & Gowda, 1989; Kasturi & Gowda, 1990).

In the present study a successful attempt is made to demonstrate the presence of a distinct 'neurotoxic potential' involved in the interaction with the nervous system apart from the catalytic site on the venom PLA₂ molecule.

MATERIALS AND METHODS

Materials

Vipera russelli venom was purchased from Irula Snake Catcher's Industrial Cooperative Society Limited, Madras (Lot no. ISCICS-II). CM-Sephadex-C-25 (4.5 meq/g) and Sephadex-G-50 were from Pharmacia Fine Chemicals, Uppsala, Sweden. Linoleic acid, agarose, Freund's complete and incomplete adjuvants and α -nitroso- β -naphthal were purchased from Sigma Chemical Company, St Louis, MO. All other chemicals and solvents were of analytical grade. The solvents were redistilled before use. Male Swiss Wistar mice, weighing 20-22 g, were used for all pharmacological studies. Female rabbits, weighing ~1.5 g, were used for the preparation of antibodies.

Purification of PLA₂ enzyme VRV PL-VIII_a from V. russelli venom

VRV PL-VIII_a was purified to homogeneity as described elsewhere (Kasturi & Gowda, 1989).

Preparation of VRV PL-VIII_a toxoid and production of anti-VRV PL-VIII_a antibody

VRV PL-VIII_a toxoid was prepared by formalin treatment, according to the method of Kondo *et al.* (1970). Antibodies were raised in rabbits as described elsewhere (Kasturi & Gowda, 1990)

Preparation of γ -globulin and detection of antibodies

γ -Globulin was prepared from rabbit antiserum injected with VRV PL-VIII_a toxoid, by precipitation with ammonium sulphate as described by Heide & Schwick (1973). The γ -globulin fraction thus obtained is termed anti-PL-VIII_a Ig. The Ouchterlony agar gel double-diffusion technique was used to detect precipitating antibodies, as described by Williams & Chase (1971).

Preparation of synaptosomes from rat brain

The procedure for isolating synaptosomal fraction was based on the method of Cotman *et al.* (1970). Briefly, the cerebral cortices from three to five male rats were used for each experiment. Removal of the cortex was achieved within 40 seconds of decapitation. The cortex was washed thoroughly in ice-cold saline and homogenized in 0.32 M sucrose, pH 7.0 (20% w/v). The homogenate was diluted to 10% w/v in 0.32 M sucrose and centrifuged at 1000 g for 5 min. The supernatant was discarded. The precipitate was resuspended in a minimum amount of 0.32 M sucrose and applied to a gradient consisting of 7 ml each of 4%, 6% and 13% w/v Ficoll (Sigma) in 0.32 M sucrose and centrifuged at 64,000 g for 45 min. The synaptosomal fraction settled at the 6–13% interface was collected with 4 volumes of 0.32 M sucrose, pH 7.0, and centrifuged at 50,000 g for 20 min, which resulted in pellet formation.

Assay of PLA₂ activity using egg phosphatidyl choline (PC) and synaptosomes as substrates

PLA₂ was assayed by estimating the free fatty acid released, as described in earlier papers (Kasturi & Gowda, 1989), using egg PC and synaptosomes as the substrates. PLA₂ activity is expressed in terms of nmoles of fatty acid released per min per mg of protein. In order to study the effect of anti-PL-VIII_a Ig on the PLA₂ activity of VRV PL-VIII_a, VRV PL-VI, VRV PL-V and whole *V. russelli* venom, the enzyme samples were incubated with various concentrations of anti-PL-VIII_a Ig (w/w) for different lengths of time at 37° in phosphate-buffered saline (PBS), pH 7.5, and the PLA₂ assay was carried out by using both egg PC and synaptosomes as substrates. The typical reaction mixture (1 ml) contained 400 nmole of egg PC (or synaptosomes, when synaptosomes were used as substrate), in 400 μ l of 0.05 M Tris-HCl buffer, pH 7.5, 100 μ l of diethyl ether, 40 mM Ca²⁺, and 50 μ g of enzyme sample with different concentrations of anti-PL-VIII_a Ig in 400 μ l of PBS, pH 7.5. PLA₂ activity is expressed in terms of amount of fatty acid released in nmoles per min per mg of protein.

Assay of indirect haemolytic activity

A semi-quantitative indirect haemolytic assay was employed to study the effect of anti-PL-VIII_a Ig on the haemolysis induced by PLA₂ enzyme VRV PL-VIII_a, VRV PL-V, VRV PL-VI and whole *V. russelli* venom, as described by Viswanath, Kini & Gowda (1987).

Lethal potency

In order to study the effect of anti-PL-VIII_a Ig on the lethal potency of VRV PL-VIII_a, VRV PL-V, VRV PL-VI and whole *Vipera russelli* venom, these toxins were preincubated with various concentrations of anti-PL-VIII_a Ig at 37° for 1 hr and injected separately by i.p. route into groups of eight mice at twice their LD₅₀ doses. The number of deaths occurring within 24 hr was noted.

Oedema-inducing activity

The effect of anti-PL-VIII_a Ig on the oedema-inducing activity of all the enzymes and whole venom was checked by incubating these proteins with different concentrations of anti-PL-VIII_a Ig for different lengths of time at 37° in PBS (pH 7.5) (Vishwanath *et al.*, 1987). The oedema ratio (the weight of the oedematous leg \times 100/wt of the normal leg), at 5 μ g concentration of each protein, and minimum oedema dose (amount of protein causing an oedema ratio of 120%) in the presence of different concentrations of anti-PL-VIII_a Ig were calculated.




Figure 1. Ouchterlony immunodiffusion of antigens against antibody; immunodiffusion was carried out in 1% Agar gel. The central well contained anti-PL-VIII_a Ig (100 μ g). (a) VRV PL-VIII_a; (b) VRV PL-V; (c) VRV PL-VI; (d) whole *V. russelli* venom (50 μ g each).

Table 1. Effect of anti-PL-VIII_a Ig on the PLA₂ activity of VRV PL-VIII_a, VRV PL-V, VRV PL-VI and Crude *V. russelli* venom with egg PC used as substrate

Conc. antibody (anti-PL-VIII _a Ig) added (μg)	Incubation of Ag-Ab: time in hr at 37°	Specific activity*			
		VRV PL-VIII _a	VRV PL-V	VRV PL-VI	Crude venom
—	1	111 ± 2	52 ± 5	84 ± 2	56 ± 5
	2	111 ± 3	56 ± 0.5	81 ± 1	57 ± 2
	24	111 ± 33	58 ± 2	84 ± 0.5	5 ± 0.5
50	1	111 ± 2	56 ± 2	86 ± 1	57 ± 2
	2	106 ± 0.5	55 ± 2	81 ± 3	58 ± 0.5
50	24	111 ± 3	56 ± 0.5	84 ± 1	59 ± 3
100	1	105 ± 0.5	53 ± 0.5	86 ± 0.5	60 ± 3
	2	113 ± 2	53 ± 3	84 ± 1	60 ± 2
100	24	115 ± 5	58 ± 2	81 ± 2	57 ± 0.5
1000	1	117 ± 7	55 ± 0.5	83 ± 1	57 ± 6
	2	110 ± 0.5	54 ± 2	84 ± 0.5	57 ± 0.5
1000	24	107 ± 2	58 ± 0.5	82 ± 1	56 ± 0.5

Values of specific activity are expressed as mean ± SD ($n=4$).

*Specific activity is expressed in terms of nmoles of fatty acid liberated/min/mg of protein. 50 μg of enzyme sample were taken per assay.

Table 2. Effect of anti-PL-VIII_a Ig on the indirect haemolytic activity of VRV PL-VIII_a, VRV PL-V, VRV PL-VI and whole *V. russelli* venom

Conc. anti-PL-VIII _a Ig added (μg)	Indirect haemolytic activity of antigen* (% haemolysis)			
	VRV PL-VIII _a	VRV PL-V	VRV PL-VI	Whole venom
0	18 ± 1	9 ± 2	12 ± 0.5	7 ± 2
25	16 ± 3	10 ± 0.5	11 ± 2	7 ± 0.5
100	17 ± 0.5	9 ± 0.5	12 ± 1	8 ± 1
250	17 ± 2	9 ± 5	12 ± 0.5	7 ± 1
500	18 ± 1	10 ± 2	12 ± 1	7 ± 3

Antigen and anti-PL-VIII_a Ig were incubated together at 37° for 1 hr before the assay.

The complete haemolysis of the erythrocytes by the addition of 10 ml distilled water was taken as 100%. Values are presented as mean ± SD of four independent determinations.

*25 μg of antigen were used for all assays.

Coagulation tests

Anti-coagulant activity was routinely determined by prothrombin times, according to the method of Quick (1966). The effect of anti-PL-VIII_a Ig on the anti-coagulant potency of VRV PL-VIII_a, VRV PL-V and VRV PL-VI was determined.

RESULTS

When the rabbit antiserum and anti-PL-VIII_a Ig were tested on gel diffusion plates against the antigens VRV PL-VIII_a, VRV PL-VI, VRV PL-V and whole *V. russelli* venom, by Ouchterlony immunodiffusion technique, one precipitin line was formed in all the cases (Fig. 1), in contrast to preimmune serum which did not give any precipitin line on agar gel plates with any of these antigens.

Anti-PL-VIII_a Ig could neither inhibit the catalytic activity of VRV PL-VIII_a, VRV PL-V, VRV PL-VI and whole *V. russelli* venom, when egg PC was used as a substrate at the concentrations shown in Table 1, nor have any effect on their indirect haemolytic activity at the concentrations indicated in Table 2. When synaptosomes were used as the substrate, anti-PL-VIII_a Ig completely inhibited the PLA₂ activity of all three neurotoxic PLA₂ and of whole *V. russelli* venom when present at an antigen-antibody (Ag-Ab) ratio of 1:5 and 1:10 (w/w) and a preincubation time of 1 hr. However, anti-PL-VIII_a Ig did not have any effect when present at an Ag-Ab ratio of 1:2 (w/w) and a preincubation time of 24 hr (Table 3).

When VRV PL-VIII_a was mixed with anti-PL-VIII_a Ig at the ratio of 1:2 (w/w) and injected to animals at twice the LD₅₀ dose (10.6 mg/kg body weight), five out of eight animals died within 5–8 hr of injection. All the animals showed neurotoxic symptoms, such as hindlimb paralysis, respiratory distress, convulsion and lacrimation. Three animals recovered from the neurotoxic effects, as the symptoms vanished slowly 12 hr after injection. When VRV PL-VIII_a and anti-PL-VIII_a Ig were mixed in the ratio of 1:5 and 1:10 (w/w), there was absolutely no mortality and no neurotoxic symptoms observed in any of the animals injected with these Ag-Ab mixtures. When VRV PL-V was mixed with anti-PL-VIII_a Ig in the ratio 1:2 (w/w) and injected at twice the LD₅₀ dose (3.6 mg/kg body weight) all the animals exhibited neurotoxic symptoms and died within 3–4 hr of injection; when mixed in the ratio 1:5, six out of eight animals died, but the survival time had increased from 2–3 hr to 4–6 hr. All the animals showed symptoms of neurotoxicity; however, two animals recovered and the neurotoxic symptoms vanished 10 hr after injection. When this antigen and antibody were mixed in the ratio of 1:10, all the animals survived and none of them showed neurotoxic symptoms. VRV PL-VI was mixed with anti-PL-VIII_a Ig in the ratio of 1:2 and 1:5 (w/w) and injected at twice the LD₅₀ dose (7 mg/kg body weight). All the animals exhibited neurotoxic symptoms and died within 3 hr of injection. When this Ag-Ab ratio was raised to 1:10, all the

Table 3. Effect of anti-PL-VIII_a Ig on the PLA₂ activity of VRV PL-VIII_a, VRV PL-V, VRV PL-VI and crude *V. russelli* venom when synaptosome was used as a substrate

Conc. anti-PL-VIII _a Ig added (μg)	Incubation of Ag-Ab: time in hr at 37°	Specific activity			
		VRV PL-VIII _a	VRV PL-V	VRV PL-VI	Crude venom
—	1	333	215	499	510
—	24	339	213	489	511
40	1	338	216	491	515
40	24	339	212	498	505
100	1	0	0	0	0
100	24	ND	ND	ND	ND
200	1	0	0	0	0
200	24	ND	ND	ND	ND

20 μg of enzyme sample were taken per assay; specific activity is expressed in terms of nmoles of fatty acid liberated/min/mg of protein.

Values of specific activity are expressed as mean of four independent determinations. The SD in all the cases was less than 1.

Table 4. Effect of anti-PL-VIII_a Ig on the oedema-inducing activity of VRV PL-VIII_a, VRV PL-V, VRV PL-VI and whole *V. russelli* venom

Conc. anti-PL-VIII _a Ig added (μg)	Oedema ratio (%) (5 μg)			
	VRV PL-VIII _a	VRV PL-V	VRV PL-VI	Whole venom
—	158 ± 4.3	159 ± 3	160 ± 1	166 ± 0.5
10	153 ± 2.8	161 ± 1	151 ± 9	164 ± 2
25	156 ± 9.6	158 ± 0.5	155 ± 3	163 ± 5
50	160 ± 5.7	159 ± 3	156 ± 1	167 ± 0.5

Values of oedema ratio are expressed as mean ± SD ($n=6$).

Minimum oedema dose is defined as the amount of protein causing an oedema ratio of 120%. It remained constant in all the cases. Minimum oedema dose of VRV PL-VIII_a, 1 μg; VRV PL-V, 0.1 μg; VRV PL-VI, 0.85 μg; whole *V. russelli* venom, 0.2 μg.

Table 5. Effect of anti-PL-VIII_a Ig on anti-coagulant activity of *V. russelli* PLA₂ enzymes

	Clotting time (seconds)	
	Without anti-PL-VIII _a Ig	With anti-PL-VIII _a Ig
Control	19 ± 1	19 ± 1
VRV PL-VIII _a	55 ± 2	20 ± 2
VRV PL-V	46 ± 2	19 ± 1
VRV PL-VI	41 ± 3	19 ± 1

10 μg of PLA₂ enzyme were used for all assays.

The values of clotting time are expressed as mean ± SD ($n=6$).

The antigen and antibody were incubated together at 37° for 10 min before the assay.

10 μg of anti-PL-VIII_a Ig were used for all interaction studies.

injected animals survived without any neurotoxic symptoms. When whole *V. russelli* venom was mixed with anti-PL-VIII_a Ig in the ratio of 1:5 (w/w) and injected at twice the LD₅₀ dose (8.2 mg/kg body weight), all eight animals died, but the survival time had increased from 3–4 hr to 10–12 hr. All the animals exhibited neurotoxic symptoms after 6 hr. When this Ag-Ab ratio was raised to 1:10 (w/w), although all the animals died 10–12 hr after injection, none of them exhibited symptoms of neurotoxicity.

Anti-PL-VIII_a Ig could not inhibit the oedema-inducing activity of VRV PL-VIII_a, VRV PL-V, VRV PL-VI and whole *V. russelli* venom at the concentrations given in Table 4. All three PLA₂ (VRV PL-VIII_a, VRV PL-V and VRV PL-VI) studied from *V. russelli* venom exhibited anti-coagulant potency by increasing the clotting time of human plasma. The anti-coagulant activity of all the three enzymes were completely inhibited in presence of anti-PL-VIII_a Ig at the concentrations indicated in Table 5.

DISCUSSION

Injection of VRV PL-VIII_a toxoid into rabbits elicited the formation of specific antibodies. Formation of a single precipitin line against VRV PL-VIII_a indicates the presence of more than one antibody to VRV PL-VIII_a. The possibility of this being a non-immune precipitate is ruled out because no precipitin lines were ever observed between VRV PL-VIII_a and preimmune serum from the same rabbit. Anti-PL-VIII_a Ig gave a single identical precipitin line against VRV PL-V and VRV PL-VI, which are potent neurotoxins from *V. russelli* venom, suggesting that anti-PL-VIII_a Ig cross-reacts with the other neurotoxins studied from *V. russelli* venom. As the basic PLA₂ having neurotoxic effects from *V. russelli* venom are of similar molecular size, they migrate to the same distance on agar gel plates, leading to the formation of a single precipitin line even in case of whole *V. russelli* venom.

Anti-PL-VIII_a Ig could not inhibit the *in vitro* PLA₂ activity of VRV PL-VIII_a when egg PC was used as a substrate, suggesting that the region involved in the catalytic activity of VRV PL-VIII_a is poorly immunogenic. It also suggests that the animal which receives PLA₂ enzyme as an antigen may have

PLA₂ enzyme with a similar catalytic site in its own body and thus fails to recognize the catalytic site as foreign. Though anti-PL-VIII_a Ig cross-reacted with other neurotoxins studied (VRV PL-V and VRV PL-VI) and whole *V. russelli* venom on agar gel plates, it had no effect on their *in vitro* PLA₂ activity when egg PC was used as the substrate, suggesting that anti-PL-VIII_a Ig cannot recognize the catalytic site of the enzymes. The fact that the anti-PL-VIII_a Ig has no influence on the indirect haemolytic activity of these PLA₂ isoenzymes further confirms that the interaction between the anti-PL-VIII_a Ig and the enzyme does not affect the catalytic site.

Anti-PL-VIII_a Ig offered complete protection against the lethality and symptoms of neurotoxicity of VRV PL-VIII_a, VRV PL-V and VRV PL-VI, the potent neurotoxins of *V. russelli* venom and the neurotoxic symptoms of whole venom without affecting the *in vitro* PLA₂ activity when using egg PC as the substrate. This indicates that the anti-PL-VIII_a Ig may be recognizing the molecules as a neurotoxin.

This suggestion is further confirmed by the studies carried out using synaptosomes. Synaptosomes (synaptic bodies) are defined as pinched off nerve endings or synaptic boutons which, after homogenization, reseal to form a discrete particle. Anti-PL-VIII_a Ig inhibited the PLA₂ activity of the neurotoxins and whole *V. russelli* venom when synaptosomes were used as the substrate. This can be explained on the basis of the following fact. In synaptic transmission blockade, there are two functionally separate steps: (i) binding of PLA₂ to the specific synaptic site through a neurotoxic potential, which is unrelated to the enzyme activity; this is a primary prerequisite for neurotoxicity; and (ii) perturbation of the synaptic membrane by PLA₂ action, which is a secondary step (Kini & Evans, 1989). So initially, the neurotoxin will have to bind to a particular site on the synaptosomes, then the PLA₂ activity will bring about the hydrolysis of phospholipids in the synaptosomes. In the absence of anti-PL-VIII_a Ig, the neurotoxins bind to synaptosomes and further facilitate the PLA₂ activity of the toxin. But in the presence of anti-PL-VIII_a Ig, the neurotoxins were incapable of binding to the synaptosomes. The site on the neurotoxin responsible for binding to the nervous system or synaptosome (neurotoxic potential) is being masked in the presence of anti-PL-VIII_a Ig, which in turn has inhibited the neurotoxins from binding to the synaptosomes. Anti-PL-VIII_a Ig is masking this particular site, but the catalytic site is free as the catalytic activity *in vitro* using egg PC as the substrate remained unaltered. So the site on the neurotoxins responsible for binding to the target site of the nervous system or synaptosomes (neurotoxic potential) is independent of the catalytic site. As anti-PL-VIII_a Ig selectively recognizes the neurotoxic potential, this antibody has been termed anti-neurotoxic antibody. Though the importance of PLA₂ activity in neurotoxicity cannot be completely neglected as it plays a secondary role causing the perturbation of the structure of synaptic membrane by hydrolysing the phospholipid, neurotoxic potential, which is distinct from the catalytic site, plays a primary role in the synaptic transmission blockade mechanism.

The fact that the catalytic site and the neurotoxic potential are distinct on a PLA₂ molecule is also strengthened by previous results. (i) The enzyme VRV PL-V, upon aggregating into a pentameric form, loses its lethality and symptoms of neurotoxicity completely, while the catalytic activity is increased by twofold (Jayanthi *et al.*, 1989). (ii) The antibodies prepared

against the same aggregated PLA₂ VRV PL-V were capable of inhibiting the lethality and symptoms of neurotoxicity of VRV PL-V, VRV PL-VI and VRV PL-VIII_a without affecting their catalytic activity (Kasturi & Gowda, 1990). Anti-PL-VIII_a Ig, which was unable to inhibit the catalytic activity of the neurotoxic PLA₂ and whole *V. russelli* venom, also could not inhibit its oedema-inducing activity, suggesting that the enzyme activity may be directly responsible for oedema induction. This suggestion is further strengthened by the following observations: (i) Aristolochic acid, an alkaloid [8-methoxy-6-nitrophenanthro (3-4-d)-1,3-dioxole-5-carboxylic acid] from the medicinal plant *Aristolochia radix*, inhibits the catalytic activity and oedema-inducing activity of a PLA₂ TFV PL-X from *Trimeresurus flavoviridis* venom (Vishwanath *et al.*, 1987); (ii) inhibition of oedema induction of human synovial fluid PLA₂ in a dose-dependent manner is positively correlated with *in vitro* inhibition of PLA₂ activity. Alkylation of HSF-PLA₂ with p-bromophenacyl bromide concomitantly inhibits both enzyme and oedema-inducing activity (Vishwanath, Fawzy & Franson, 1988). Based on these results, it is suggested that the catalytic activity of PLA₂ is positively correlated with *in vivo* oedema induction.

The fact that anti-PL-VIII_a Ig completely inhibited the anti-coagulant potencies of three neurotoxic PLA₂ isoenzymes without affecting their catalytic activity suggests that PLA₂ activity alone is not responsible for anti-coagulant activity. The present results are in accordance with the results of Kini, Nancy & Evans (1988), as they identified four non-enzymatic polypeptides from *Naja nigricollis crawshawii* venom as having anti-coagulant potency.

Though many attempts are being made to nullify the toxicity of pure toxins or whole venom by using polyclonal antibodies raised against them (Kondo *et al.*, 1979; Rosenfeld & Kelen, 1966; Ownby, Colberg & Odell, 1984; Pakmanee *et al.*, 1987), there are no reports explaining the relationship between the catalytic activity and pharmacological properties making use of these antibodies. However, there are reports on attempts relating PLA₂ activity to the toxicity of the enzymes by chemical modification studies, which suggests that there are two separate but perhaps overlapping regions existing within the molecule and these regions are responsible, respectively, for the pharmacological and catalytic activity of the enzyme (Rosenberg, 1986). The present study, along with previous results (Jayanthi *et al.*, 1989; Kasturi & Gowda, 1990) supports the hypothesis put forward by Kini & Iwanaga (1986a) and Kini and Evans (1989), as it clearly demonstrates the presence of a distinct neurotoxic potential on the neurotoxic PLA₂ apart from the catalytic site.

ACKNOWLEDGMENT

S. Kasturi and L. M. S. Rudrammaji thank the University Grants Commission, New Delhi, India, for financial assistance.

REFERENCES

- COTMAN C., BROWN D.H., HARRELL B.W. & ANDERSON N.G. (1970) Analytical differential centrifugation: an analysis of the sedimentation properties of synaptosomes, mitochondria and lysosomes from rat brain homogenates. *Arch. Biochem. Biophys.* **136**, 436.
- HEIDE K. & SCHWICK H.G. (1973) Preparation of gamma-globulin. In: *Handbook of Experimental Immunology* (ed. D.M. Weiv), Vol. 1, pp. 61-64. Academic Press, NY, London.

- JAYANTHI G.P., KASTURI S. & GOWDA T.V. (1989) Dissociation of catalytic activity and neurotoxicity of a basic phospholipase A₂ from Russell's viper (*Vipera russelli*) venom. *Toxicon*, **27**, 875.
- KASTURI S. & GOWDA T.V. (1989) Purification and characterization of a major phospholipase A₂ from Russell's viper (*Vipera russelli*) venom. *Toxicon*, **27**, 229.
- KASTURI S. & GOWDA T.V. (1990) Detection, using antibodies of pharmacologically active sites, apart from the catalytic site, on venom phospholipase A₂. *Toxicon*, **28**, 91.
- KINI R.M. & EVANS H.J. (1989) A model to explain the pharmacological effects of snake venom phospholipases A₂. *Toxicon*, **27**, 613.
- KINI R.M. & IWANAGA S. (1986a) Structure–function relationships of phospholipases. I. Prediction of presynaptic neurotoxicity. *Toxicon*, **24**, 527.
- KINI R.M. & IWANAGA S. (1986b) Structure–function relationships of phospholipases. II. Charge density distribution and the mytotoxicity of presynaptically neurotoxic phospholipases. *Toxicon*, **24**, 895.
- KINI R.M., NANCY C.H. & EVANS H.J. (1988) Nonenzymatic inhibition of coagulation and platelet aggregation from *Naja nigricollis* venom are cardiotoxins. *Biochem. Biophys. Res. Commun.* **150**, 1012.
- KONDO H., KONDO S., SADAHIRO S., YAMAUCHI I., OHSAKA A. & MURATA R. (1970) Preparation and immunogenicity of habu (*Trimeresurus flavoviridis*) toxoid. In: *Toxins of Animal and Plant Origin* (eds A. Devries and E. Kochva), Vol. 3, pp. 845–859. Gordon and Breach Science Publishers, London.
- OWNBY C.L., COLBERG T.R. & ODELL G.V. (1984) A new method for quantitating hemorrhage induced by Rattle snake venoms: ability of polyvalent antivenom to neutralize hemorrhagic activity. *Toxicon*, **22**, 227.
- PAKMANEE N., PIYASIRIKUL S., TAMPITAG S., PHANUPHAK P. & CHUTZ-VONGEE S. (1987) The effect of antiphospholipase A₂ from *Vipera russelli* venom in local tissue necrosis, *First Asia–Pacific Congress on Animal Plant and Microbial Toxins*, organised by the Asia–Pacific Section of the International Society of Toxinology.
- QUICK A.J. (1966) Prothrombin time (one stage procedure). In: *Hemorrhagic Diseases and Thrombosis*, 2nd edn, p. 391. Lea and Febiger, Philadelphia.
- ROSENBERG P. (1986) The relationship between enzymatic activity and pharmacological properties of phospholipases in natural poisons. In: *Natural Toxins Animal, Plant and Microbial* (ed. J.B. Harris), pp. 129–164. Oxford Science Publications, Clarendon Press, Oxford.
- ROSENFELD G. & KELEN E.M.A. (1966) Cross neutralization of the coagulant activity of some snake venoms by antivenins. *Toxicon*, **4**, 7.
- VISHWANATH B.S., FAWZY A.A. & FRANSON R.C. (1988) Edema inducing activity of phospholipase A₂ purified from human synovial fluid and inhibition by aristolochic acid. *Inflammation*, **12**, 549.
- VISHWANATH B.S., KINI R.M. & GOWDA T.V. (1987) Characterization of three edema inducing phospholipase A₂ enzymes from habu (*Trimeresurus flavoviridis*) venom and their interaction with the alkaloid aristolochic acid. *Toxicon*, **25**, 501.
- WILLIAMS C.A. & CHASE M.W. (1971) Qualitative analysis of antigen–antibody reaction in gels. In: *Methods in Immunology and Immunochemistry* (eds C.A. Williams, and M.W. Chase), Vol. III, pp. 118–174, Academic Press, New York.